drugset / Trial / NCT02121080
Study of the Safety and Tolerability of REGN2222(SAR438584) in Healthy Adult Volunteers
RandomizedParallel-groupQuadruple-blindBasic science
Summary
This is a phase 1, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetic (PK) profile, and immunogenicity of REGN2222 ascending in cohorts of healthy adult volunteers.
Timeline
- Start
- 2014-05
- Primary completion
- 2015-02
- Completion
- 2015-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Suptavumab | Monoclonal antibody | — | — |
Indications
No indication recorded.